The Hereditary Neuropathy Foundation (HNF) is holding an externally-led, patient-focused drug development meeting for Charcot-Marie-Tooth disease (CMT) and inherited neuropathies (IN) on Friday, September 28, 2018 at the College Park Marriott Hotel and Conference Center in Hyattsville, MD.
This groundbreaking meeting provides an opportunity for patients and caregivers to meet with clinicians, regulatory agencies (eg. The National Institute for Health [NIH] and Food and Drug Administration [FDA]), insurance companies, and pharmaceutical companies with a goal of sharing the real-life challenges and unmet medical needs of patients with CMT with these stakeholders.
"This is an unprecedented time for the CMT community. The first CMT clinical trials are now reaching late-stage development, and additional pipeline clinical research is scheduled to take place in 2019. It's vital for all stakeholders to understand the life-altering impact that CMT has on patients and families," said Allison Moore, Founder and CEO of HNF. "This opportunity ensures patient perspectives are considered throughout the drug development continuum. We, as patients, are now steering the direction of our futures and have a responsibility to make our voices heard."Next Story